Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP NEWS IN BRIEF
September 17, 2001
- DIAGNOSTIC NEWS IN BRIEF
September 17, 2001
- Healthcare Reform: 30% Copayment for the Insured to Be Focused on
September 17, 2001
- Thorough Quality Control for Imported Medical Devices Called For by PMSB
September 17, 2001
- Hodanren Opposes Raising the Age Limit to 75 for Elderly Healthcare Services
September 17, 2001
- PMSB Budget Related to Medical Devices Focuses on Quality, Prioritization of Review
September 17, 2001
- 3 New Drugs Including Biapenem Recommended for Approval
September 17, 2001
- Enforcement of US/EC MRA Expected to Be Delayed: FDA Officer
September 17, 2001
- NDA Data Disclosure Procedures Notified
September 17, 2001
- MEDICAL DEVICE NEWS IN BRIEF
September 17, 2001
- JETRO Looks Into Social Security Systems in Major Countries
September 17, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
September 17, 2001
- REGULATORY NEWS IN BRIEF -1-
September 17, 2001
- Club Atmosphere in Contributing to Industry People: Mr Kodama of Pharma Delegates
September 17, 2001
- REGULATORY NEWS IN BRIEF -2-
September 17, 2001
- We Are Sure to Reach \100 Billion by Boosting Sales of Bonalon, Onealfa: Dr Naruchi of Teijin
September 17, 2001
- Dementia to Affect 10% of Elderly Citizens in 2036: Expert
September 17, 2001
- PhRMA Proposes Actual Transaction Price Reimbursement System
September 17, 2001
- Korosho to Conduct Surveys on Terminal Care in FY2002
September 17, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 17, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…